Actively Recruiting
Open-Label Study Evaluating Safety, Pharmacokinetics, and Preliminary Efficacy of WBC100 Capsules in Adults with Relapsed or Refractory Acute Myeloid Leukemia
Led by Hangzhou Weben Pharma Co., Ltd · Updated on 2026-10-16
36
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effectiveness of WBC100 capsules in adults with relapsed or refractory acute myeloid leukemia RR AML. This phase 1 trial aims to understand how well patients tolerate WBC100 and whether it can help induce remission in this challenging leukemia type. Participants will take WBC100 capsules orally once daily in 28-day treatment cycles. The study includes a dose-escalation phase where doses increase stepwise from 0.5 mg to 3.0 mg, followed by a dose expansion phase at 2.5 mg once daily. Treatment continues until disease progression, unacceptable side effects, or participant withdrawal. Throughout the study, participants will undergo regular safety checks including adverse event monitoring and lab tests. Blood samples will be collected to study how the drug behaves in the body. Researchers will assess remission status using established criteria and monitor outcomes such as dose-limiting toxicities and overall survival over a two-year period. The total study duration extends until December 2026.
CONDITIONS
Brief Title
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Research Team
W
Wu Shuigao, M.S
Z
Zheng Meng, PM
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here